Bernhard Geierstanger

Bernhard Geierstanger has extensive work experience in the biotechnology and pharmaceutical industry. Bernhard is currently the Co-founder and Chief Technology Officer at Firefly Biologics since June 2022. Prior to this, they worked at Merck from October 2019 to May 2022 as the Executive Director of Protein Engineering and Modalities, Discovery Biologics.

Before joining Merck, Geierstanger spent over two decades at GNF, where they held various roles including Executive Director of Biotherapeutics, Director of Protein Design and Function, Director of Protein Engineering, Associate Director of Protein Engineering, Group Leader of Protein Modification Technology, Group Leader of NMR Spectroscopy, and Group Leader of Protein Array Technology. At GNF, they were involved in preclinical development of novel biotherapeutics, platform technology development for protein engineering, and the generation of biotherapeutics.

Earlier in their career, Geierstanger worked at Goethe University as a Postdoc/Research Scientist from April 1997 to October 1999, and at Stanford University as a Postdoctoral Fellow from January 1995 to April 1997.

Bernhard Geierstanger completed their education in a chronological manner. Bernhard first attended Hochschule München University of Applied Sciences from 1983 to 1988, where they pursued a degree in Physikalisch-Chemische Technik and obtained a Dipl. Ing. (FH). Following this, they enrolled at Oregon State University from 1988 to 1990, where they pursued further studies in Biophysics and Biochemistry and earned a Master of Science (MS) degree. Lastly, from 1990 to 1994, Geierstanger attended the University of California, Berkeley, where they pursued a Doctor of Philosophy (PhD) degree in Biophysics.